TREG

Our group manufactures Ex Vivo Expanded CD4+ CD127 lo/-CD25+ Alloantigen- Reactive Regulatory T Cells (arTregs) and polyclonal CD4+ CD127 lo/-CD25+ regulatory T cells (polyclonal Tregs) for clinical trials in patients who have received solid organ tranplant or who have been diagnosed with an autoimmune disease. The goal is to test the safety and efficacy of these cells to prevent solid organ rejection or to improve symptoms of autoimmune disease.

Primary location: San Francisco United States